Roche breast cancer drug 'helps patients live longer': study

A drug developed by Swiss giant Roche to treat an aggressive form of breast cancer has been shown to extend patients' lives by almost 16 months, researchers said Sunday.

Patients who took the new Perjeta drug in combination with chemotherapy and Roche's older anti-cancer drug Herceptin lived a median of 56.5 months, compared to 40.8 months for people in the trial who weren't on Perjeta, Roche said in a statement.

"Adding Perjeta to treatment with Herceptin and chemotherapy resulted in the longest survival observed to date in a clinical study of people with HER2-positive ," said Sandra Horning, Roche's chief medical officer and head of global product development.

The 15.7-month longer survival time marked "a magnitude of improvement we rarely see in clinical trials in advanced cancer," she added.

The trial involved more than 800 patients with previously untreated HER2-positive metastatic .

HER2 is a protein that makes grow. HER2-positive cancer makes up about 15 to 20 percent of breast cancers, and tends to be more difficult to treat.

Metastatic cancer is a cancer that has spread to other parts of the body.


Explore further

Advanced breast cancer: Benefits of Trastuzumab (Herceptin) outweigh the risk of harm

© 2014 AFP

Citation: Roche breast cancer drug 'helps patients live longer': study (2014, September 29) retrieved 15 July 2019 from https://medicalxpress.com/news/2014-09-roche-breast-cancer-drug-patients.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more